Stockwinners Market Radar for July 26, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:19 EDT Cathie Wood's ARK Investment bought 113K shares of Toast today

20:17 EDT Cathie Wood's ARK Investment bought 1.77M shares of Shopify today

19:36 EDT PayPal up 5.8% after report of activist stake held by Elliott Management

18:30 EDT Microsoft now up nearly 5% to $264 after providing Q1 guidance

18:14 EDT Revolution Medicines director buys $5.0M in common stock - In a regulatory filing, Revolution Medicines disclosed that its director Thilo Schroeder bought 250K share of common stock on July 22nd in a total transaction size of $5.0M.

17:49 EDT Microsoft says over 4M people have streamed 'Fortnite' via Cloud Gaming - Says meeting customers where they are with Azure. Says Game Pass offers "best value" in gaming industry. Says over 4M have streamed "Fortnite" via Xbox Cloud Gaming. Comments taken from Q4 earnings conference call.

17:32 EDT Luxfer reports Q2 adjusted EPS 36c, consensus 33c - Reports Q2 revenue $109.5M, consensus $106.4M. "We continued to maneuver successfully through uneven supply chain conditions to deliver for our customers in the Q2, and I appreciate the dedication of our employees in rising to this challenge," said Andy Butcher, CEO. "The Elektron segment again led our financial performance this quarter and, as expected, Gas Cylinders posted sequential increases in both sales and profitability. While monitoring the ongoing evolution of the macroeconomy, we are encouraged by the broad-based demand seen across our portfolio as we prepare to execute on our long-term growth opportunities."

17:03 EDT Teradyne falls 8% to $90.33 after Q2 earnings, below-consensus guidance

16:55 EDT Pzena Investment to become private company - Pzena Investment Management announced that it has entered into an agreement to become a private company through a transaction in which holders of PZN Class A common stock will receive $9.60 per share in cash. Under the terms of the definitive agreement, PZN will merge with and into a newly formed subsidiary of its operating company, Pzena Investment Management, in an all-cash transaction that implies an enterprise value for PZN of approximately $795M. The $9.60 per share price represents a premium of 49% to PZN's closing stock price on July 26, and a premium of approximately 46% over the 90-calendar day volume weighted average price. PZN plans to maintain its regular quarterly dividend of 3c per share for the third quarter of 2022, which the Board declared earlier. Upon completion of the transaction, Pzena Investment Management will be a privately-held company owned by the existing partners of PIM. All of Pzena Investment Management's leadership and investment professionals are anticipated to remain in place and will retain substantially all of their equity interest in the business. The transaction is expected to close in the fourth quarter of 2022, subject to approval by PZN stockholders, including a special approval of holders of a majority of the Class A shares not held by persons who will remain as investors in PIM following the closing, receipt of applicable regulatory approvals, and other customary closing conditions. In connection with the proposed transaction, PZN entered into a voting agreement with certain members of PZN's management team, as a result of which all outstanding shares of Class B common stock will be voted in favor of the transaction.

16:43 EDT Palomar announces new partnership with Omaha National Group - Palomar Holdings announced it has entered into a two-year arrangement with new partner Omaha National Group. Palomar's partnership provides a key entry point through its admitted subsidiary, Palomar Specialty Insurance Company , acting as the insurer in California, supporting Omaha National's workers compensation product in California's admitted market. Omaha National, through its managing general agent, Omaha National Underwriters, will be overseeing the insurance operations including underwriting, risk management and claims. This partnership represents further progress towards Palomar's strategic growth initiatives in PLMR-FRONT. Palomar operates with a significant competitive advantage and is a key resource in permitting non-licensed insurance companies and reinsurers to access the United States primary insurance market.

16:39 EDT Algoma Steel notified by USW local 2724 agreement ratified - Algoma Steel Group reports it has been notified by United Steelworkers Local 2724, the union representing its technical, professional and front-line supervisory employees, that their members have successfully ratified their collective agreement, providing an enhanced economic package for their members and importantly setting out the process to transition the workforce to electric arc steelmaking. Discussions are ongoing between the Company and the hourly employees represented by USW Local 2251, and the Company continues to work toward reaching an agreement before the contract expires on July 31, 2022. Algoma President and Chief Executive Officer, Michael Garcia commented on the development, "I extend sincere thanks to the negotiating committees for their concerted efforts to work through the issues in a timely manner, Together we have made great strides in Algoma's transformation, and we are on track to position the Company for a secure, sustainable future as a leading producer of green steel. We will continue to work as a team, remain committed to the plan, and maintain forward momentum."

16:32 EDT Glory Star New Media regains Nasdaq compliance - Glory Star New Media Group announced it received notification from the Listing Qualifications Department of The Nasdaq Stock Market that it has regained compliance with the minimum bid price requirement of $1.00 per share under the Nasdaq Listing Rules. On July 25, Nasdaq provided confirmation to the company that for at least 10 consecutive business days, from July 11 to July 22 the closing bid price of the company's ordinary shares has been at $1.00 per share or greater. Accordingly, the company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

16:32 EDT Summit Therapeutics appoints Maky Zanganeh as co-CEO - Summit Therapeutics announced that Maky Zanganeh has been appointed as co-CEO and president, effective immediately. Zanganeh was formerly the company's COO, having served in that capacity since she joined the company as an employee in November 2020, and remains a member of the company's board of directors. Prior to joining Summit, Zanganeh founded Maky Zanganeh and Associates in 2015, and from 2008 to 2015, she held multiple leadership positions at Pharmacyclics, Inc., culminating in her role as COO.

16:29 EDT AMSC announces $40M of new energy power system orders - AMSC announced $40M of new energy power systems orders. This includes orders for reactive compensation, enclosed capacitor banks, harmonic filters, voltage controllers, rectifiers and transformers. More than half of the revenue from these orders is expected to be recognized in fiscal year 2022. "Tailwinds in our key markets are driving an acceleration in bookings of our new energy power systems solutions," said Daniel P. McGahn, Chairman, President and CEO, AMSC. "The semiconductor industry is expected to continue to increase capital spending in the coming years. The move to decarbonization and to achieve energy independence among numerous nations is also expected to translate into broadened adoption of renewable power systems across the globe. We believe these dynamics have the capability to support demand of our products for the medium to long term."

16:27 EDT Wells Fargo raises quarterly dividend to 30c from 25c per share - Dividend is payable to stockholders of record on Aug. 5, 2022, as approved today by the Wells Fargo board of directors.

16:20 EDT Exxon Mobil makes two more discoveries offshore Guyana - ExxonMobil has made two new discoveries offshore Guyana to the southeast of the Liza and Payara developments in the Stabroek block. The discoveries at Seabob and Kiru-Kiru are the sixth and seventh in Guyana this year, with the total number of discoveries in Guyana at more than 25. The Seabob-1 well encountered approximately 131 feet (40 meters) of high-quality hydrocarbon-bearing sandstone and was drilled in 4,660 feet (1,421 meters) of water by the Stena Carron drill ship. The Kiru-Kiru-1 well encountered approximately 98 feet (30 meters) of high-quality hydrocarbon-bearing sandstone and was drilled by the Stena DrillMAX in 5,760 feet (1,756 meters) of water. Drilling operations at Kiru-Kiru are ongoing. "ExxonMobil and its partners continue to accelerate exploration, development and production activities for the benefit of all stakeholders, including the people of Guyana," said Liam Mallon, president of ExxonMobil Upstream Company. "The resources we are investing in and discovering offshore Guyana will provide safe, secure energy for global markets for decades to come."

16:19 EDT Matador Resources raises FY22 oil production view to 21.4M-22M Bbl - Previous view 21M-22M Bbl.

16:17 EDT Energy Transfer LP raises quarterly dividend by 15% to 23c per share - The dividend will be paid on August 19, 2022 to unitholders of record as of the close of business on August 8, 2022.

16:16 EDT Cintas raises quarterly dividend 21% to $1.15 per share - The dividend is payable on September 15, 2022 to shareholders of record at the close of business on August 15, 2022.

16:14 EDT Chipotle jumps 7% to $1,414 after Q2 profit beats estimates

16:13 EDT Chipotle reports Q2 in-restaurant sales increased 35.9% - In Q2: In-restaurant sales increased 35.9%, while digital sales1 represented 39.0% of food and beverage revenue. Operating margin was 15.3%, an increase from 13.0%. Restaurant level operating margin was 25.2% 2, an increase of 70 basis points.

16:12 EDT United Insurance completes reorganization plan - United Insurance Holdings announced the completion of a reorganization plan to consolidate its four Florida domiciled insurance carriers into two, creating a more efficient operating structure going forward. Effective May 31, 2022, the Company merged Family Security Insurance Company, Inc. into United Property & Casualty Insurance Company (United) with United being the surviving entity. Effective June 1, 2022, the Company merged Journey Insurance Company (Journey) into American Coastal Insurance Company with American Coastal Insurance Company being the surviving entity. As part of the merger, $30 million of Journey's capital was redistributed to United. The Company estimates current year catastrophe losses incurred for the second quarter ending June 30, 2022 of approximately $21 million before income taxes (approximately $17 million after tax), net of expected reinsurance recoveries. The Company estimates adverse development on prior year losses incurred for the second quarter ending June 30, 2022 of approximately $8 million before income taxes (approximately $6 million after tax), net of expected reinsurance recoveries. The Company's cumulative loss position resulted in the need for a valuation allowance on its deferred tax assets. UPC Insurance estimates the valuation allowance for the second quarter ending June 30, 2022, to be approximately $59 million which will decrease net earnings by approximately $44 million.

16:09 EDT Sutro:1st patient dosed in study with Merck for cytokine derivative for cancer - Sutro Biopharma (STRO) announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck (MRK) for the development of a novel cytokine derivative therapeutic for the treatment of cancer. As a result of this milestone, Sutro will receive a $10 million payment from Merck. "We are pleased with the progress of this next-generation biologic candidate, from discovery to clinical development for patients with advanced or metastatic solid tumors," said Bill Newell, Chief Executive Officer of Sutro. "This milestone reflects the strong synergistic collaboration between Merck's biological expertise in the field of immuno-oncology and Sutro's prowess in designing, engineering, and manufacturing complex biologics that incorporate site-specific conjugation. We are excited about the potential this therapeutic may have for cancer patients."Under the terms of the July 2018 collaboration agreement between Sutro and Merck, Sutro has been primarily responsible for preclinical research and development, as well as manufacturing, of cytokine derivatives utilizing Sutro's proprietary cell-free protein synthesis and site-specific conjugation platforms, XpressCF and Xpress CF+ Merck has exclusive worldwide rights to therapeutic candidates derived from the collaboration.

16:07 EDT Alphabet CFO says 'consistent investments' reflected in 'solid' Q2 performance - Ruth Porat, CFO of Alphabet and Google, said: "Our consistent investments to support long-term growth are reflected in our solid performance in the second quarter, with revenues of $69.7B in the quarter, up 13% versus last year or 16% on a constant currency basis. We are focused on responsible capital allocation in support of our growth opportunities."

16:07 EDT Boyd Gaming sees closing Pala Interactive deal around year-end - The Company continues to make progress toward completing its previously announced acquisition of Pala Interactive for cash consideration of $170 million. Pending the receipt of all remaining regulatory approvals, the Company anticipates it will close on the acquisition around year-end. In addition, the Company plans to open Sky River Casino near Sacramento, California in early September 2022. The Company has a seven-year management agreement to operate Sky River on behalf of the Wilton Rancheria Tribe.

16:06 EDT Alphabet CEO says Q2 performance driven by Search and Cloud - Sundar Pichai, CEO of Alphabet and Google, said: "In the second quarter our performance was driven by Search and Cloud. The investments we've made over the years in AI and computing are helping to make our services particularly valuable for consumers, and highly effective for businesses of all sizes. As we sharpen our focus, we'll continue to invest responsibly in deep computer science for the long-term."

16:06 EDT Alphabet reports Q2 Google advertising revenue $56.29B vs. $50.44B a year ago - Reports Q2 YouTube ads revenue $7.34B vs. $7.0B in same quarter of prior year. Reports Q2 Google Search and other revenue $40.69B vs. $35.85B a year ago. Reports Q2 total Traffic Acquisition Costs $12.21B vs. $10.93B a year ago.

16:05 EDT Microsoft reports Q4 LinkedIn revenue up 26%, up 29% in constant currency

16:04 EDT First Community increases quarterly cash dividend 7.41% to 29c per share - The company declared a quarterly cash dividend to common shareholders of 29c per common share, an increase of 2c, or 7.41%, over the quarterly dividend declared in the same quarter of 2021. The quarterly dividend is also an increase of 2c from the dividends declared in the previous two quarters of 2022. The quarterly dividend is payable to common shareholders of record on August 5 and is expected to be paid on or about August 19.

16:03 EDT Texas Instruments sees 2022 effective tax rate about 14%

15:07 EDT Vizio up 3% after Protocol report on Comcast acquisition talks

14:24 EDT Texas Capital acquires 42,000 common shares - In a regulatory filing, Texas Capital Bancshares director Robert Stallings disclosed the purchase of 42,000 common shares of the company on July 22 at a price of $56.57 per share.

14:03 EDT Aurinia says USPTO to institute trial on Inter Partes review of Lupkynis patent - Aurinia Pharmaceuticals announced that it has received notice regarding the U.S. Patent Office, or USPTO, Patent Trial and Appeal Board decision to institute trial on the Inter Partes review filed by Sun Pharmaceuticals, directed at U.S. Patent No. 10,286,036. This patent is related to the Lupkynis dosing protocol for lupus nephritis. Patent No. 10,286,036 was issued to Aurinia in support of the unique eGFR pharmacodynamic dosing protocol used within the company's clinical trials, and extends patent protection for Lupkynis to 2037. "Regardless of the final outcomes of the IPR, the company has filed a standard form patent term extension for its existing composition of matter patent, which, if granted, would extend the term of that patent by 5 years to October 2027. A determination on patentability, relative to the IPR, is expected on or prior to July 26, 2023," the company stated. "While this decision is disappointing, as we have stated from the start of his process, we will vigorously defend this patent. This patent already had significant review at the USPTO before being approved as being a valid patent by that office and we are fully prepared to continue legal proceedings to protect our intellectual property," added Peter Greenleaf, President and CEO, Aurinia Pharmaceuticals.

13:49 EDT Meta increases prices of Meta Quest 2 headsets - Meta said that, in order to cintue investing in "moving the VR industry forward for the long term," it is adjusting the price of Meta Quest 2 headsets to $399.99 for the 128GB version and $499.99 for the 256GB version starting on August 1, 2022. Reference Link

12:19 EDT Douglas Elliman expands into Basalt, Colorado - Douglas Elliman Realty announced that it has expanded its footprint in Colorado. With the opening of a new office in Basalt - its fourth office in the state - the company said it is well positioned to bring its market expertise and unparalleled service to the Mid-Valley communities of Basalt, Carbondale and Glenwood Springs, near Aspen where Douglas Elliman consistently sets record-breaking sales. Located at 310 Market Street, the 800-square-foot office will provide space for both agents and staff members. "Like the increasing numbers of homebuyers and investors drawn to the region, we see tremendous opportunity in Colorado's Mid-Valley," said Scott Durkin, CEO, Douglas Elliman Realty. "With the current inventory and growing demand for new developments, we expect to substantially increase our market share."

12:08 EDT Adidas: Currency netural revenues grew 4% during Q2 - Based on preliminary numbers, adidas' currency-neutral revenues grew 4% during the second quarter. "In euro terms, sales increased 10% to EUR 5.596 billion. The company's gross margin declined 1.5 percentage points to a level of 50.3% and operating margin reached 7.0% during the second quarter (2021: 10.7%). Net income from continuing operations was EUR 360 million in Q2 (2021: EUR 387 million) supported by a one-time tax benefit of more than EUR 100 million due to the reversal of a prior year provision."

12:04 EDT Ultralife awarded $4.6M to supply VAA to defense contractor - Ultralife Corporation has been awarded a purchase order valued at approximately $4.6M to supply its Vehicle Amplifier-Adaptors to a global prime defense contractor. Ultralife's VAA platform provides the soldier with an enhanced range of digital voice and data communications and operational flexibility. Shipments are expected to commence in 2022.

11:33 EDT HMH appoints Benita Flucker as chief equity, inclusion officer - HMH announced the appointment of Benita Flucker as Chief Equity and Inclusion Officer. In this new position, Flucker will oversee HMH's multifaceted commitment to building and delivering curriculum solutions and services that foster a holistic understanding of the world and honor the diverse students, educators and communities HMH serves each day. Working closely with HMH's CPO Alejandro Reyes, who will continue to lead HMH's employee-focused diversity, equity and inclusion efforts, Flucker will also be an essential guiding voice for HMH's employee community as leader and strategic advisor for its nine employee resource groups. Flucker's appointment builds upon more than a decade of service at HMH, most recently in the role of senior vice president of the cross-functional Enterprise Development Strategy and Services team.

11:05 EDT California Energy Commission selects NORESCO to develop efficiency standards - NORESCO announced it has been awarded a new, three-year contract to help the California Energy Commission develop and adopt the state's building energy code for 2025. California's Building Energy Efficiency Standards are updated every three years to guide the construction of new and existing buildings toward the state's clean energy goals. NORESCO has worked with the CEC to advance one of the nation's most efficient building energy standards, Title 24, Part 6 of the California Code of Regulations, for more than 15 years.

10:43 EDT Bank First National to acquire Hometown Bancorp for $124M - Bank First Corporation (BFC) announced the signing of an Agreement and Plan of Merger with Hometown Bancorp, a Wisconsin state-chartered bank, under which Bank First has agreed to acquire 100% of the common stock of Hometown in a combined stock-and-cash transaction. Under the terms of the Agreement and Plan of Merger, each Hometown shareholder will have the option to receive either $29.16 in cash or 0.3962 of a share of Bank First's common stock in exchange for each share of Hometown common stock, subject to customary proration and allocation procedures, such that no less than 70% of Hometown shares will receive stock consideration and no greater than 30% will receive cash consideration. The aggregate consideration is valued at approximately $124M, based on the closing price of Bank First common stock as of July 22, 2022 of $75.23 per share. Upon completion of the merger, Tim McFarlane will assume the role of President and will join the Board of Directors of Bank First, N.A. He will also be nominated to the Bank First Corporation Board of Directors. Mike Molepske will continue serving as CEO and Chairman of the Boards of Directors of Bank First Corporation and Bank First, N.A. The Boards of Directors of Bank First and Hometown have approved the Agreement and Plan of Merger. The closing of the transaction is expected to be in the fourth quarter of 2022, subject to customary closing conditions, including regulatory approval, approval by Hometown's shareholders, and obtaining a conversion date from UFS and Fiserv. As of June 30, 2022, Hometown had approximately $627.6M in consolidated assets, $421.2M in gross loans, $538.7M in deposits and $65.5M in consolidated stockholders' equity. Based on the financial results as of June 30, 2022, the combined company, inclusive of projected balances to be acquired from the proposed acquisition of Denmark Bancshares, Inc., will have total assets of approximately $4.3B, loans of approximately $3.3B and deposits of approximately $3.7B.

10:36 EDT Walmart partner with WALDO to offer affordable contact lenses - Walmart and WALDO are partnering to make eyecare more accessible and affordable. Walmart is the first exclusive retailer to offer WALDO. The lenses are enriched with essential vitamins, including B12, to help refresh and rejuvenate eyes. At $23.86 for a 30-pack of the Hydra Boost Daily Lenses, customers can save 13%-84% off the cash price of comparable branded daily disposable contact lenses at Walmart, which translates into a savings of up to $552 a year at Walmart.

10:11 EDT Autonomoy selects AutoNation as Dealer of Record - Autonomy has partnered with AutoNation. The partnership will support Autonomy's electric vehicle product expansion from the Tesla Model 3 into several automaker brands as well as its geographic expansion across the United States, leveraging AutoNation's nationwide footprint. As Autonomy's "Dealer of Record," AutoNation will support Autonomy's planned acquisition, over the next 12-18 months of up to 20,000 electric vehicles from automakers that produce the most sought-after electric vehicles. AutoNation will provide vehicle preparation and delivery services in connection with Autonomy customer activations, as well as maintenance, repair, and reconditioning services for its growing fleet of subscription vehicles.

10:07 EDT Eagle Bancorp raises quarterly dividend 10% to 13.75c per share - Eagle's board of directors increased its quarterly cash dividend by 10% to 13.75c per share on July 21, 2022. The dividend will be payable September 2, 2022 to shareholders of record August 12, 2022. The current dividend represents an annualized yield of 2.81% based on recent market prices.

10:03 EDT RxLive raises $5M Series A funding round - RxLive announced a $5M Series A funding round. The digital health startup's round was led by SpringTide with participation by Cardinal Health. RxLive has raised a total of $8M to date. As value-based pharmacy care models expand beyond the retail pharmacy setting RxLive will use the funding to expand its engineering, analytics, and sales and marketing teams, with particular investment in the continuous improvement of its AI and the functionality of its medication management platform.

09:52 EDT Manulife Financial cautions investors regarding Obatan offer for share - Manulife has been notified of an unsolicited mini-tender offer made by Obatan to purchase up to 500,000 Manulife common shares, or approximately 0.026% of the common shares outstanding, at a price of 12.00 per share. Manulife is in no way associated with Obatan and does not recommend or endorse acceptance of this unsolicited offer. Manulife cautions shareholders that the mini-tender offer has been made at a price below the current market price for Manulife shares. The offer represents a discount of 34.04% and 34.21%, respectively, below the closing prices of Manulife common shares on the TSX and NYSE on July 14, 2022, the last trading day before the mini-tender offer was commenced, and a discount of 37.67% and 37.71%, respectively, below the closing prices on the TSX and NYSE on July 25, 2022. Shareholders should carefully review the Obatan offer documents and current market price for Manulife shares, and consult their investment advisors regarding any offer they may receive and review with their advisors all options for their investment in Manulife shares.

09:49 EDT Miniso falls after Blue Orca Capital releases short report - Blue Orca Capital announced a short position in Miniso, writing in a report published on its website: "Rather than operate an independent network of franchisees, our seven-month investigation of Chinese corporate records and store level data indicates, in our opinion, that hundreds of stores are secretly owned and operated by MINISO executives or individuals closely connected to the chairman." The chairman siphoned hundreds of millions from the public company through "opaque Caribbean jurisdictions as the middleman in a crooked headquarters deal," the firm contends. Blue Orca says Miniso "is a brand in decline, with revenues down 40% from pre-IPO peak, large-scale pre-Covid store closures and franchise fees which have fallen 63% over the past two years." The firm says the stock "should trade at a fraction of its current share price." Miniso in morning trading is down 6% to $6.80.

09:37 EDT VRAX Stock trading resumes

09:34 EDT Alkaline Water identifies $2M in additional annual expense reductions - Alkaline Water announced it has identified approximately $2M more in annual expense reductions and margin enhancements through its company-wide pathway to profitability evaluation and review. The company has now identified an estimated $7M in annual cost-saving measures, once fully implemented.

09:32 EDT Global Tech says Liberty continuing to process digital dividend request forms - Global Tech Industries Group announced that its transfer agent, Liberty Stock Transfer is continuing to process the request forms coming in from shareholders to receive their digital dividend, some coming in from those who have downloaded the form from the corporate website, and some coming in from the recent, physical mailing the company undertook in mid-June.

09:29 EDT GM CEO sees announcement on fourth battery plant in 'not too distant future' - Asked on the company's earnings call about the timing of an announcement on a fourth battery plant, General Motors CEO Mary Barra said she expects an announcement in the "not too distant future" and added that news on the plans will come "definitely this year."

09:28 EDT Lexaria licensee Premier Wellness launches Ko brand - Lexaria Bioscience announced that its exclusive Japanese Licensee, Premier Wellness Science officially launched its first generation of its new cannabidiol products under the brand "Ko", on July 21, 2022 for the Japanese consumer market. Premier will create its own e-commerce infrastructure and digital marketing campaigns in collaboration with its parent company, Premier Anti-Aging. For wholesale sales, Premier will work with a large third-party Japanese-based distribution company also listed on the Tokyo Stock Exchange to expand sales channels. Originally founded in 1898, it is a large distributor and logistics supplier for cosmetics, OTC pharmaceuticals and nutraceuticals to wholesalers, retailers and more; and, shipped more than 3.5 billion products in its most recent fiscal year, comprised of over 50,000 products and over 50,000 retail stores of distribution. The "Ko" brand is focused on the endocannabinoid system and circadian rhythm to support the health and wellness of all people, highlighted by the concept of wellness for all and will contain CBD and other botanical extracts. Ko-branded products containing Lexaria's DehydraTECH delivery technology are expected to be introduced during Q2 2023, following rigorous product development and formula optimization. Premier is working diligently to establish its new brand while also looking towards extensive distribution for the DehydraTECH-enabled products to be developed and sold. Lexaria notes the extensive capabilities of Premier, Parent, and PALTAC - all expected to contribute to the eventual widespread introduction of DehydraTECH-CBD products within the Japanese marketplace. Under the terms of the license agreement with Lexaria as previously announced on June 3, 2022, Premier purchased the rights to DehydraTECH technology for the Japanese non-pharmaceutical market for use with CBD and hemp ingredients in oral liquid and non-liquid products, as well as for topical, hair-care, lip-care and cosmetics products. In order to retain ongoing exclusivity, the negotiated minimum quarterly payments to Lexaria begin September 1, 2022 and, during the first five years of the Agreement, amount to $4,527,500. Additional payments beyond five years are required to keep the license in good standing, in which case the license for the Japanese market is perpetual. In addition to the Payments, Lexaria will also receive royalty revenue from DehydraTECH licensed product sales, which are anticipated to be significantly greater than the minimum Payments if Premier is capable of meeting its expected revenue targets. If Premier achieves even their worst-case projected penetration into the Japanese non-pharmaceutical CBD market, then based on their projections Lexaria could expect to receive annual payments of over $5 million by the fifth year of the contract.

09:24 EDT Verizon introduces Lenovo ThinkPad X13s - Verizon is bringing the full capabilities of 5G into the hands of businesses with the launch of the Lenovo ThinkPad X13s. The ThinkPad X13s is the first business-ready laptop to take advantage of the full capabilities of Verizon 5G Ultra Wideband. The Verizon 5G Ultra Wideband network, available in select areas, delivers a top-of-the-line 5G experience, delivering speeds up to 10 times faster than 4G LTE. This 5G Ultra Wideband connected laptop can empower employees with fast, secure connections, allowing them to work on the go. Verizon's 5G Ultra Wideband offers high speed, low latency and massive capacity, allowing employees to transfer huge files and make HD video calls outside of the office faster and safer than with public Wi-Fi.

09:24 EDT Rapid7 introduces layered context capabilities for InsightCloudSec - Rapid7 announced new layered context capabilities within the company's InsightCloudSec offering, the company's fully-integrated Cloud-Native Security Platform. With the addition of layered context functionality, security teams are provided a consolidated, unified, and real-time view of risk signals, including misconfigurations and public exposure, across their environment.

09:22 EDT APA Corp. publishes 2022 Sustainability Report - APA Corporation published its 2022 Sustainability Report, highlighting the achievement of numerous Environment, Social and Governance goals throughout 2021 while tracking progress made on ESG commitments for 2022. The report is available here, along with a summary fact sheet detailing report highlights. The quality and breadth of data provided in the report stems from the company's work to continuously enhance disclosures and measurements of ESG progress. This year, APA updated the Task Force on Climate-related Financial Disclosures analysis using the International Energy Agency's World Energy Outlook, provided detailed disclosure of 2021 air and water data at the country level, increased board diversity in ethnicity and global leadership experience, and reduced recordable injury counts by 76% compared to our 10-year average.

09:20 EDT Equifax to acquire Midigator, terms not disclosed - Equifax is expanding its global footprint in digital identity and fraud prevention with a definitive agreement to acquire Midigator, a provider of post-transaction fraud mitigation solutions. With the rise of global ecommerce sales, expected to hit $5.5 trillion in 2022, transaction disputes and chargebacks are also surging. Midigator's highly automated, data-driven chargeback prevention and chargeback dispute management solutions complement the Equifax Kount Identity Trust Global Network, which uses award-winning Artificial Intelligence to link trust and fraud data signals from 32 billion digital interactions, 17 billion unique devices, and five billion annual transactions across 200 countries and territories. With global omnichannel digital payments expected to grow from 2.6 billion users in 2020 to over 4.4 billion in 2025, dispute and chargeback rates present growing problems for businesses around the world. Founded in 2013, Midigator offers a technology platform designed to not only automate the dispute response process, but to provide the real-time data businesses need to know why chargebacks are occurring in the first place and better understand their customers. Midigator has prevented more than 2.7 million chargebacks. The resulting granular, post-transaction data and digital signals complement the Equifax Kount dataset and augment AI-driven Kount preventative fraud products to combat the illegitimate chargebacks known as "friendly" fraud as well as criminal fraud activities. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2022. The acquisition is not anticipated to have a material impact on 2022 Equifax financial results. As part of the transaction, LLR Partners, who invested in Midigator in 2018, will exit the business. Raymond James served as financial advisor and Goodwin Proctor served as legal advisor to Midigator in this transaction. King & Spalding LLP served as the legal advisor to Equifax. Once the transaction closes, Midigator will become part of the Equifax USIS business unit.

09:16 EDT IMAC announces exploration of strategic alternatives - IMAC Holdings announced that its board of directors has initiated an exploration of strategic alternatives. As part of this process, the board will consider a wide range of options for the company including, among other things, a potential merger, spin-off, sale, or other strategic transaction for one or more of its key business units or assets. "As our company continues to expand into complementary revenue streams, we believe the time is right to investigate a range of strategic alternatives with the intent to pursue profitable growth and maximize shareholder value," said Jeffrey Ervin, IMAC's Chief Executive Officer. "We have developed a range of regenerative and organic applications for spinal health and wellness and expect to publish record revenue in our 2nd quarter filing as evidence of this progress. We simply see a disconnect between asset values we have developed and the value our assets may have to partners." There can be no assurance that this process will result in the company pursuing a particular transaction or other strategic outcome. IMAC has not set a timetable for completion of this process, and it does not intend to disclose further developments unless and until it determines that further disclosure is appropriate or necessary. IMAC has retained Joseph Gunnar & Co. LLC as its exclusive financial advisor to assist in the review process.

09:15 EDT Core Scientific enters colocation agreement to up its hosting business by 75MW - Core Scientific announced that it has entered into a colocation agreement to increase its hosting business by 75MW. The recently signed colocation agreement will generate approximately $50M in annual revenue when the ASIC servers are fully deployed. In addition, the agreement provides for prepayments sufficient to fund the additional infrastructure required to host the 75MW. Server deployments will begin in the third quarter of this year, with full deployment to be completed during 2022. With the addition of these units, the company expects to be operating approximately 325,000 ASIC servers in its data centers before year end.

09:14 EDT Neovasc announces FDA approval of protocol supplement to COSIRA-II trial - Neovasc announced the United States Food and Drug Administration has approved a protocol supplement to the COSIRA-II Investigational Device Exemption Trial. The approval expands the number of patients eligible for treatment in the trial and adds two previously planned imaging sub-studies designed to provide insights into the safety and mechanism of action of the Neovasc Reducer. The timing of the approval is ahead of the Company's internal target and will allow for additional patients to be treated. The newly approved supplement adds a single, non-randomized arm to the existing protocol that allows enrollment of patients who are believed to benefit from Reducer implantation to reduce their angina symptoms, but who do not otherwise qualify for the randomized arm. These patients are well defined within the protocol and include patients with non-obstructive coronary artery disease who were previously ineligible for treatment. In addition, the expansion allows patients with predominantly right-sided ischemia, and those unable to perform a treadmill test due to amputation, to be included. All patients in the newly approved arm will receive a Reducer device per protocol. The two imaging sub-studies, utilizing Computed Tomography and Positron Emission Tomography, aim to provide further support for the Reducer's safety profile and mechanism of action. There are over two million angiograms performed per year in the United States, most of which are performed on patients with angina. Nearly 40% of patients receiving angiograms do not have obstructive coronary artery disease. While approximately 35% of patients with obstructive coronary disease are women, the percentage of patients with non-obstructive disease that are women approaches 55%. The newly added arm in the COSIRA-II study provides an opportunity to study the Reducer in the non-obstructive population. COSIRA-II is a randomized, double-blind, placebo-controlled trial investigating the safety and effectiveness of the Reducer for patients suffering from refractory angina. The primary endpoint of the trial is change in exercise tolerance testing time via a modified Bruce protocol between baseline and six-month follow-up. The study is planned to randomize 380 patients at up to 50 sites in the United States and Canada and the primary study analysis will still be performed on the randomized population. The newly added arm allows for up to 270 additional patients. There is no change to the sample size in the original randomized arm and Neovasc still expects to complete enrollment on schedule by the end of 2023.

09:12 EDT Rockley Photonics announces strategic partnership with contract research group - Rockley Photonics Holdings Limited announced a new partnership with a top ten, global contract research organization that provides full-service clinical development services to biopharmaceutical customers. Under the agreement, the CRO and Rockley will collaborate on strategic programs to integrate Rockley's health monitoring solutions into clinical research studies, including its Bioptx biosensing wristband, cloud services, and other elements of its biomarker sensing platform for continuous, near real-time, non-invasive measurement of multiple biomarkers. The addition of Rockley's wearable devices and artificial intelligence capabilities to clinical research has the potential to enable decentralized trials, increase the frequency and accuracy of vital sign monitoring, and expand the range of biomarker information collected from research participants, whether at a clinic or in a remote location. In this collaboration, the CRO is expected to use Rockley-powered remote monitoring wearables as a tool for researchers to better understand various factors affecting the health and well-being of trial participants. The Rockley Bioptx wristbands will potentially allow the CRO to collect in-depth data about an expanded range of biomarkers, including core body temperature, blood pressure, heart rate, blood oxygen, and body hydration, among others. By gathering and analyzing data on key biomarkers, this new partnership has the potential to enhance the opportunity for the Rockley platform to provide pharmaceutical companies and healthcare professionals with a more thorough understanding of how specific treatments and interventions affect a patient's overall health.

09:11 EDT Winnebago appoints Casey Tubman as Newmar president - Winnebago Industries appointed Casey Tubman as President of Newmar Corporation, effective August 1, 2022. Mr. Tubman will report to President and CEO Michael Happe and will be based in Nappanee, Indiana. Tubman joins Winnebago Industries after more than 25 years in a variety of leadership and executive roles at Whirlpool Corporation, a multinational manufacturer of home appliances. He most recently served as Vice President and Global Platform Leader - Laundry where he was responsible for product development strategies and execution across five regions and all countries worldwide.

09:10 EDT IMAC Holdings Inc trading halted, news pending

09:06 EDT SuperCom signs third new GPS monitoring contract in Idaho - SuperCom announced the signing of a third new GPS monitoring contract in Idaho. The County Juvenile Department, the contracting agency, will use SuperCom's PureTrack GPS smartphone products to monitor their caseload for location compliance. SuperCom will supply its proprietary software and hardware, whereas the agency will handle equipment installation and client monitoring. The contract is set up as a per unit per day lease, with billing at the end of each month generating recurring revenues.

09:04 EDT ZoomInfo appoints Tomer Gershoni as Chief Security Officer - ZoomInfo announced the appointment of Tomer Gershoni as its Chief Security Officer. Gershoni will lead ZoomInfo's information security team, overseeing physical and digital security and privacy efforts and leading ZoomInfo's work to safeguard internal and external company data. He'll work closely with Simon McDougall, ZoomInfo's Chief Compliance Officer, and ZoomInfo's privacy team to ensure the limited, non-sensitive data the company collects and stores remains protected. Gershoni will also serve as a resource for customers, advising them on best practices for accessing, processing, and possessing ZoomInfo's data.

09:03 EDT BAE Systems awarded five-year contract extension by Army - The U.S. Army has awarded BAE Systems a five-year contract extension for operations at the Radford Army Ammunition Plant with a ceiling value of up to $1.3B. The operating contract will extend through December 31, 2026. This award demonstrates the strong relationship between BAE Systems and the Army for operating the facility that produces critical munitions and explosives for the U.S. Department of Defense.

09:02 EDT Intapp expands functionality of DealCloud through partnership with Cherre - Intapp announced expanded functionality of DealCloud through a new partnership with Cherre, a real estate data management and analytics platform. In this partnership, Cherre will connect asset ownership, building information, and zoning, tax, and mortgage data and integrate it directly into the DealCloud platform using the Cherre API. DealCloud users will see these data points alongside firmwide proprietary information, resulting in an augmented view of current and prospective investments. "We are excited to work with Cherre to provide the contextual information CRE investors rely on directly in the deal management tool they use on a daily basis," said Frank Spadafora, Real Estate Industry Principal at Intapp. "The power of DealCloud and Cherre together will vastly improve the identification of target assets and the speed and accuracy of due diligence, leading to better decision making around the acquisition of properties."

08:58 EDT UPS sees 2H22 U.S. Domestic revenue growth of about 5.5% - Sees 2H22: International revenue growth in low-single digits; Supply Chain Solutions revenue about $9B; Consolidated operating margin about 13.6%. Expects currency headwinds in 2H22.

08:56 EDT Verizon, Microsoft partner to off Xbox All Access - Verizon said, "Xbox is here! Starting July 28, Verizon once again proves it's the ultimate network for gamers by teaming up with Microsoft to offer Xbox All Access in select stores and online. With Xbox All Access and Verizon, you get a next-gen Xbox console and hundreds of games, including day one releases with Xbox Game Pass Ultimate, all on the network America relies on. Xbox All Access pairs perfectly with Verizon's fast and reliable mobile and home connections - 5G Ultra Wideband and Verizon Home Internet - both available in select areas. Whether you prefer massive multiplayer online games, fancy yourself a solo RPG purist or just want to jump into the fray with your closest friends, Verizon has you covered."

08:56 EDT UPS sees FY22 free cash flow about $9B

08:55 EDT UPS says continuing to win in most attractive parts of the market - Expects volume growth rates to "improve slightly" in 2H22 vs. 1H22.

08:50 EDT Siyata Mobile announces availability of SD7 rugged MCPTT device - Siyata Mobile announces its SD7 rugged mission-critical push-to-talk device is now available for customers who need the integrated solutions from TASSTA.

08:48 EDT BK Technologies awarded $8.9M in purchase orders from USDA Forest Service - BK Technologies announced that it has received six purchase orders for a total value of approximately $8.9 million from the United States Department of Agriculture Forest Service for its KNG mobile and BKR 5000 portable communications technology. The purchase orders are part of the Company's 5-year Blanket Purchase Agreement with the U.S. Department of Agriculture, announced in May 2021, and reflect the agency's commitment to its lifecycle replacement program designed to migrate to newer, more effective portable communications platforms. Additionally, the Company announced that effective July 1, 2022 it has opened a second production line for the BKR 5000 at its manufacturing facility in West Melbourne, Florida.

08:44 EDT BK Technologies gets $8.9M in purchase orders from from USDA Forest Service - BK Technologies announced that it has received six purchase orders for a total value of approximately $8.9M from the United States Department of Agriculture Forest Service, USFS, for its KNG mobile and BKR 5000 portable communications technology. The purchase orders are part of the Company's 5-year Blanket Purchase Agreement, BPA, with the U.S. Department of Agriculture, announced in May 2021, and reflect the agency's commitment to its lifecycle replacement program designed to migrate to newer, more effective portable communications platforms. John Suzuki, CEO of BK Technologies commented, "We're pleased to continue our strong relationship with the USFS as they continue to upgrade their mobile equipment and technology with our BR 5000 portable communications platform. The USFS is committed to ensuring the safety and efficiency of their personnel tasked with wildland fire prevention and fire rescue across vast landscapes, and our BKR 5000 plays a pivotal role providing reliable communications capabilities in rugged environments. In addition to providing durable and consistent communications technology, the BKR 5000 is compatible with legacy radios and equipment, as the agency conducts a systemwide transition. We look forward to continuing to support the USFS with our state-of-the-art communications platform and equipment."

08:42 EDT Definitive Healthcare launches Passport Express product - Definitive Healthcare announced the general availability of Passport Express, the newest product in the Passport Analytics Suite. Building on the integration of Analytical Wizards into Definitive Healthcare, Passport Express combines comprehensive analytics from the Passport Analytics Suite with therapy-specific data from Definitive Healthcare in a single package. The off-the-shelf healthcare commercial intelligence in Passport Express helps biopharma companies rapidly answer critical business questions to accelerate pre-launch planning and maximize in-market brand performance.

08:41 EDT Coca-Cola watching closely for signs of changing consumer behavior

08:40 EDT GM CEO says supply secured for all battery materials needed to hit 2025 EV goal - General Motors CEO Mary Barra continues speaking on the company's Q2 earnings call.

08:39 EDT Tracon Pharmaceuticals announces dosing of 36th patient in ENVASARC trial - TRACON Pharmaceuticals announced the enrollment of the 36th patient in the ENVASARC pivotal trial at the 600 mg dose of envafolimab, which enables the initial independent data monitoring committee, IDMC, interim efficacy analysis to proceed. The interim analysis is expected to occur in the fourth quarter of this year. The initial IDMC interim efficacy analysis proceeds after the 36th patient has been enrolled for at least three months to permit two on study scans to determine the preliminary objective response rate. One objective response is required in each of the trial's two cohorts to continue accrual in that cohort. The first cohort includes the initial 18 patients who receive single agent envafolimab and the second cohort includes 18 patients who receive envafolimab with ipilimumab. A second IDMC interim efficacy analysis is expected in 2023 following enrollment of the 92nd patient. "We are pleased at the pace of enrollment in ENVASARC and have accrued more than 36 patients in fewer than six months since the FDA approved the amended protocol. As a result, we are currently ahead of the enrollment projection that would allow for full accrual of the 160 planned patients dosed with 600 mg of envafolimab before the end of 2023," said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. "We look forward to reporting the IDMC recommendations following the two interim safety analyses and interim efficacy analysis expected this year."

08:36 EDT Crowdstrike, JumpCloud partner for device security - JumpCloud announced it has partnered with CrowdStrike to introduce JumpCloud's full-disk encryption with secure vaulting of recovery keys, cross-OS device patching, single sign-on capabilities, and device management to the CrowdStrike ecosystem via the CrowdStrike Store, a cybersecurity app marketplace. Combining CrowdStrike's Falcon platform with JumpCloud's ability to harden the security posture of machines and quickly remediate issues ensures common customers' fleets are as secure as possible, all through the CrowdStrike Store.

08:35 EDT InPlay Oil drills three 1.5 mile ERH wells in Pembina in Q2 - The company said, "During the second quarter, InPlay drilled three 1.5 mile Extended Reach Horizontal wells in Pembina which came on production at the end of May. The average combined initial production rates of these wells over the first thirty and sixty days of production was 1,501 boe/d and 1,441 boe/d respectively, based on field estimates. The Company also completed the drilling operations of an additional two 2 mile ERH wells in Willesden Green which have currently been completed and are in the early cleanup period. Construction of a modular multi-well facility in Willesden Green began during the quarter to accommodate current and future drilling in the area. Extreme wet weather in late June delayed the start of our third quarter capital program. The program has now started with drilling operations underway on the second well of a three ERH well pad in Willesden Green which is expected to be on production in late August. The Company's released 2022 guidance is reiterated with field estimated average corporate production for the second quarter of 2022 of approximately 9,150 boe/d which includes over 5,000 bbls of a light crude oil inventory build due to difficulty trucking oil at the end of June. This is 11% higher than production in the first quarter of 2022. Current corporate production is approximately 9,550 boe/d based on field estimates, which is 16% above our average production during the first quarter of 2022. As a result of using a consistent drill crew since the beginning of the year and exceptional project execution, the two 2 mile ERH wells in Willesden Green were drilled in 10.3 and 10.7 days respectively, which were among the fastest drilling operations for 2 mile wells in the area. In comparison to the last 2 mile wells drilled by the Company in Willesden Green in 2018 drilling times improved by approximately 20% which is a positive result for the Company and is an example of InPlay's continuous drive to achieve operational efficiencies."

08:34 EDT Coca-Cola CEO: Operating environment 'asynchronous' in Q2 - Comments taken from Q2 earnings conference call.

08:33 EDT InPlay Oil announces renewal of credit facility - InPlay's Senior Credit Facility remains unchanged in lending capacity and has been renewed at $79 million comprised of a $65 million revolving facility and the remaining $14 million term facility. The borrowing base of the revolving facility has been reconfirmed at the same amount of $65 million and the term out date extended to November 30, 2022. In addition to the Senior Credit Facility, the Company's $25 million four year term facility with the Business Development Bank of Canada remains in place, providing InPlay with $104 million of total lending capacity.

08:32 EDT American Board of Radiology deploys authID's Verified - authID announced that the American Board of Radiology has deployed authID's facial biometric authentication solution Verified to help the ABR certify candidates. Following a proof-of-concept phase, the ABR signed an agreement with authID for online identity verification of candidates using Verified.

08:30 EDT General Electric sees tangible improvements in engine deliveries in 2H

08:27 EDT First Solar issues 2022 Sustainability Report - First Solar announced that it has issued its 2022 Sustainability Report highlighting its environmental, social, and governance progress. Highlights in First Solar's 2022 Sustainability Report include: A 13% year-on-year reduction in greenhouse gas emissions intensity. The company remains on track to achieve its science-based target of reducing its absolute scope 1 and scope 2 greenhouse gas emissions, from a 2008 baseline, by 34% by 2028 and net-zero emissions by 2050 in line with limiting global temperatures to 1.5 degrees Celsius. An 8% year-on-year reduction in manufacturing energy intensity and a cumulative reduction in manufacturing energy intensity per watt by 65% since 2009. First Solar's manufacturing energy intensity includes all processes, from the beginning of its manufacturing process to finished module. The company set a target to improve global energy efficiency per watt produced by 74% by 2028, from a 2009 baseline. A 32% year-on-year reduction in manufacturing water intensity and a 78% reduction since 2009. Water recycling initiatives saved more than 268 million liters of water in 2021. After surpassing a previous water intensity target seven years early, First Solar set a new target of an 87% reduction in water intensity per watt compared to its 2009 baseline. An 8% year-on-year reduction in manufacturing waste intensity and a 55% reduction since 2012. A 4% increase in women in management positions compared to 2020. First Solar's Board of Directors is 33% diverse and the company was recognized as a "3+ company" by 50/50 Women on Boards for having at least three women serve on its Board.

08:25 EDT Schlumberger awarded contract by Kosmos Energy - Schlumberger announced an award to OneSubsea and its alliance partner, Subsea 7, by Kosmos Energy Gulf of Mexico Operations for an engineering, procurement, construction and installation, or EPCI, contract for the Odd Job field in the Gulf of Mexico. Through the EPCI contract, OneSubsea, the subsea technologies, production, and processing systems business of Schlumberger, will supply a subsea multiphase boosting system, topside equipment, and a 16-mile integrated power and control umbilical. Project management, engineering, assembly and testing will be performed at the OneSubsea facilities in Bergen and Horsoy, Norway, while transport to the field and installation will be carried out by Subsea 7.

08:23 EDT Galectin Therapeutics announces $60M credit line - Galectin Therapeutics announced it entered into a $60 million unsecured line of credit facility with its chairman and largest individual stockholder, Richard E. Uihlein. Borrowings under the credit line are unsecured and at the Company's discretion through July 31, 2024. Advances under the line of credit bear interest at the Applicable Federal Rate for short term loans, which is currently 2.84%, plus 2%. Principal and interest are due on January 31, 2026 and are evidenced by convertible promissory notes that may be converted into shares of the Company's common stock at a conversion price equal to the closing price of the common stock on the date of such promissory note, but in no event less than $3.00 per share. The Company granted five hundred thousand stock purchase warrants exercisable at $5.00 per share in connection with entering into the line of credit. At the election of Mr. Uihlein, the principal and accrued interest on borrowings may be converted into the number of shares of the Company's common stock equal to the amount of principal and accrued interest on such borrowing divided by the closing price of the common stock on the date of such borrowing, but in no event less than $3.00 per share. Additionally, the Company will issue up to 1,200,000 stock purchase warrants to Mr. Uihlein ratably, at the time of borrowings under the line of credit, with exercise prices equal to 150% of the closing price of the common stock on the date of the Promissory Note evidencing such draw, but in no event more than $10.00 per share nor less than $3.00 per share.

08:22 EDT AbbVie selects NowVertical as vertical intelligence solutions partner - NowVertical Group announced a multi-year contract with AbbVie S.A.S., a Colombia-based subsidiary of AbbVie. Under the contract, NOW will implement multi-platform data engineering solutions to dramatically increase the value and application of AbbVie's data science projects. The vertically intelligent transformation efforts will increase AbbVie's data and analytics capabilities to prove out Big Data projects through the conformation of experienced and specialized Data Engineering cells. The Illinois-based biopharmaceutical company has more than 48,000 employees worldwide. AbbVie develops and markets medicines and advanced therapies to tackle some of the most complex diseases in the world, mainly immunological and oncological.

08:20 EDT GE taking more conservative view of renewable market amid current environment

08:19 EDT MoonLake signs development, manufacturing agreement with Vetter - MoonLake Immunotherapeutics announced that it has signed a Master Development Services Agreement with Vetter Pharma International GmbH, a leading global contract development and manufacturing organization for fill and finish services, ranging from development support, including clinical manufacturing, through to commercial supply. Under the agreement Vetter will be responsible for the aseptic filling of syringes with sonelokimab, and the subsequent assembly into an autoinjector combination device and packaging. Sonelokimab is MoonLake's investigational Nanobody designed to treat inflammatory disease by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. In addition, sonelokimab is designed to directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues. Development studies associated with the manufacturing of sub-cutaneous sonelokimab for clinical trials and commercial volumes have been concluded, and technical engineering batches started in Q2 2022. The first clinical Good Manufacturing Practice batches are expected to be manufactured in Q4 2022 as a complementary, second supply point alongside the current source of drug product for clinical use.

08:18 EDT Bionano Genomics announces participation at Cancer Genomics Consortium - Bionano Genomics announced its participation at the Cancer Genomics Consortium 2022 Annual Meeting with 18 events including a panel discussion, scientific platform presentations, facilitated roundtable, and poster presentations from Bionano and a wide variety of independent researchers from across the cancer genomics landscape. CGC's Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genomics for cancer research. CGC conference sessions will take place July 31- August 3, 2022, in St. Louis, Missouri with an option for virtual attendance. Bionano will exhibit its complete portfolio of products and services relevant to the cancer research community including OGM solutions, NxClinical software and laboratory services. As part of a sponsored spotlight panel, Bionano's chief medical officer, Alka Chaubey, will host a discussion titled "Optical Genome Mapping and its Integration with NGS for Clinical Research in Leukemia and Lymphoma," featuring cancer genomics experts Dr. Ravindra Kolhe, from the Medical College of Georgia/Augusta University, Dr. Yassmine Akkari, from Nationwide Children's Hospital, Dr. Rashmi Kanagal-Shamanna, from MD Anderson Cancer Center, and Dr. Brynn Levy, from Columbia University Medical Center and the New York Presbyterian Hospital. The presentation will take place Tuesday, August 2, from 4:45-5:30 PM CST in the General Session room. Four separate scientific presentations, featuring the use of OGM in cancer research will be given. Dr. Adam Smith of University Health Network will present on international working group recommendations for the use of OGM in hematological malignancy research. Dr. Ha Nguyen of MD Anderson Cancer Center will present on homologous recombination DNA repair deficiency in hematological malignancies. Dr. Thuy Phung of University of South Alabama will present on the identification of novel structural variants in angiosarcoma using OGM. Dr. Nikhil Sahajpal of Augusta University will present on the integration of OGM and a 523-gene panel for comprehensive genomic evaluation of myeloid cancers. Dr. Smith will also facilitate a roundtable discussion on the detection of gene rearrangements by OGM and NGS.

08:17 EDT DatChat's SmarterVerse enters into JV with MetaBizz - DatChat announced that its wholly-owned subsidiary, SmarterVerse has entered into a joint venture with MetaBizz to develop an all-new metaverse named "The Habytat." The Habytat will be a mobile-based social networking metaverse that will use DatChat's Dynamic Content NFT's, patented blockchain digital rights management, and micro blockchain technology to create a new social networking and commercial metaverse. The Habytat will democratize ownership in the metaverse by making land obtainable for almost anyone. The joint venture will be led by Gianfranco Lopane, who is currently the Head of Business Development at DatChat. Pursuant to the terms of the joint venture, DatChat will initially own 60 percent of the joint venture and MetaBizz will own 40 percent. Additionally, MetaBizz will contribute over twenty engineers and designers based in both North and South America.

08:14 EDT Beam Global, Volvo announces partnership to offer off-grid EV charging - Beam Global (BEEM) announced a partnership with Volvo Construction Equipment (VLVLY) that allows Volvo CE's 245 North American dealer locations to bundle Beam EV ARC off-grid charging systems with a purchase of Volvo electric equipment. This joint offering enables construction sites to rapidly deploy EV charging, without the requirement for electrical work, utility grid connections or fossil fuel generators, to power zero-emissions construction equipment that runs on the sun and does not generate a utility bill. "The construction industry has the opportunity to future-proof its business against noise, carbon emissions regulations and volatile fossil fuel costs by adopting electric machines," said Beam Global CEO Desmond Wheatley. "By providing our sustainable EV charging systems alongside Volvo's best-in-class electric machines, we are enabling that transition in the fastest, cleanest and most scalable manner available. We're proud to partner with Volvo CE in electrifying the construction business." Volvo CE currently offers five models of electric machines in North America. Now Volvo dealers can bundle transportable, off-grid solar EV charging systems with electric machine orders. Together, the EV ARC and Volvo electric machines produce zero emissions, reduce noise levels and lower energy costs.

08:12 EDT ProPhase Labs announces $6M stock repurchase plan - ProPhase Labs announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs' common stock, which will become effective three business days after the date the Company issues its quarterly earnings release for the six months ended June 30, 2022, which the Company currently anticipates issuing on August 12, 2022.

08:10 EDT The Oncology Institute acquires practice of Dr. Nutan Parikh - The Oncology Institute announced the acquisition of the practice of Dr. Nutan Parikh. The addition of Dr. Parikh's locations further strengthens TOI's position in the Nevada market and solidifies its role as a leading value-based oncology care provider. As a result of the partnership, Dr. Parikh's patients will now have access to enhanced services, including: A leading clinical research program, offering patients access to more than 170 clinical trials. Comprehensive physician dispensary services that offer convenience, savings, and resources for financial assistance to patients receiving oral chemotherapeutics and injectables. Outpatient blood transfusion, multiple convenient clinics & community-based chemotherapy treatment. Dr. Parikh and his team will continue to serve patients at their two Las Vegas-area locations 2904 W Horizon Ridge Pkwy #200, Henderson, NV 89074 and 6450 Medical Center St, Las Vegas, NV 89148 Ph# 702-471-7779 without interruption.

08:07 EDT Novavax Nuvaxovid receives expanded approval in Japan for ages 12-17 - Novavax (NVAX) announced that Nuvaxovid COVID-19 vaccine received expanded manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare for primary immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 in adolescents aged 12 through 17. Novavax has partnered with Takeda (TAK) to develop, manufacture, and distribute Nuvaxovid in Japan.

08:07 EDT Applied Genetic announces Type C meeting feedback for planned cGMP facility - Applied Genetic Technologies Corporation announced that the U.S. Food and Drug Administration provided feedback on the Current Good Manufacturing Practice design of AGTC's manufacturing facility. In its feedback from a recent Type C meeting, the FDA concurred the facility design and proposed operating procedures are appropriate to support the cGMP manufacture of recombinant AAV drug substance. In May 2022, AGTC announced that it had completed construction of the manufacturing facility's exterior structure and the FDA's feedback on the interior design of the facility helps assure the potential successful completion of next phase of construction. Initial operations at the facility are expected to begin in 4Q 2022 with GMP capabilities expected to be finalized in 1Q 2023. In May 2022, AGTC announced positive three-month interim results from the Skyline Phase 2 expansion trial of AGTC-501, demonstrating robust improvements in visual sensitivity, the trial's primary efficacy endpoint, in multiple patients three months after dosing, with a 62.5% response rate in dose group B and a 25% response rate in dose group A. This is well above the statistically significant 50% response rate the Vista Phase 2/3 trial for AGTC-501 is powered to detect.

08:06 EDT Ontrak chief medical officer Robert Accordino to depart, Judith Feld to succeed - Ontrak promoted Judith Feld to chief medical officer replacing Robert Accordino, who is leaving Ontrak Health to focus on his private practice. Feld begins immediately in the role and will report to Brandon LaVerne, co-president and COO. Feld joined Ontrak in 2019 as National Medical Director and was promoted to chief clinical strategy officer earlier this year.

08:04 EDT Trinseo pauses sale of styrenics business - Trinseo announced it has decided to pause the sale of its styrenics business. In November 2021 the company announced that it had begun work to explore the divestiture of the business and subsequently launched a formal sales process in the first quarter of 2022. The scope of the potential divestiture was expected to include the Feedstocks and Polystyrene reporting segments as well as the company's 50% ownership of Americas Styrenics. The process generated broad and significant interest from both strategic and financial parties. However, the deterioration of financing markets and the economic uncertainty created by the war in Ukraine, particularly in European energy markets, has impeded the company's ability to obtain full value for the business. The delay of the styrenics divestiture does not change the company's transformation strategy. The company intends to reevaluate a potential sale of the Business when macroeconomic conditions improve.

08:02 EDT General Electric 'making good progress' on separation, says CEO Culp - Comments taken from Q2 earnings conference call.

07:56 EDT Oramed enrolled 50% of planned 450 patients for its Phase 3 ORA-D-013-2 trial - Oramed Pharmaceuticals announced that it has enrolled and randomized over 50% of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes. ORA-D-013-2 is the second of Oramed's two Phase 3 trials being conducted under FDA Investigational New Drug Application to treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months.

07:54 EDT Small Pharma announces USPTO to grant patent for novel injectable forms of DMT - Small Pharma announces that it has received Issue Notification from the United States Patent and Trademark Office, USPTO that its patent application no. 17/459,284 will be granted on August 9, 2022 in the United States under patent no. 11,406,619 for novel injectable formulations of N,N-dimethyltryptamine, DMT, based compounds. The patent, which will represent the Company's ninth issued patent, will be the first U.S. patent grant within the Company's psychedelic portfolio, and includes formulations of DMT, the active ingredient in SPL026, and of deuterium-substituted DMT, including the active ingredient in SPL028. The patent will also protect novel injectable formulations of other known psychedelic compounds, including 5-methoxy-DMT and psilocybin. George Tziras, Chief Executive Officer, added: "This U.S. patent represents a major milestone in our development strategy. It is also timely, as we anticipate dosing completion in our SPL026 Phase IIa trial in patients with Major Depressive Disorder, and prepare for a Phase I study of SPL028 in healthy volunteers in the second half of this year. For Small Pharma's longer-term vision, the U.S. will be an important market for DMT-assisted therapies as we look to shape the future of mental health treatments."

07:52 EDT NexGel launches MEDAGEL Hydroliner Pro pads - NEXGEL announced that the Company has launched its new MEDAGEL Hydroliner Pro pads for protecting eyelashes during cosmetic extension and lift and tint services. These under-eye pads provide powerful, yet skin-friendly adhesion aimed at isolating the lower lashes. Hydroliner Pro represents NEXGEL's first patented business-to-business product application. NEXGEL's proprietary hydrogel base stays in place while being breathable, flexible and easily removable, all of which ensures maximum client comfort throughout the entire process. NEXGEL designed the patches to provide an ultra-hydrating experience to soothe the often puffy, sensitive under-eye areas and are lint- and paraben-free.

07:50 EDT Inozyme expects cash to fund operations into 2Q24

07:49 EDT Entera Bio announces formation of CSAB - Entera Bio announced the formation of its Clinical and Scientific Advisory Board, CSAB, consisting of world class experts in bone diseases, endocrinology, and metabolic disorders. In addition, the Company announced today that it will be presenting new data from its 6-month Oral PTH, EB613, Phase 2 Study in postmenopausal women with low bone mass, or osteoporosis at the 2022 Annual Meeting of the American Society for Bone and Mineral Research, ASBMR, which will take place in Austin, Texas from September 9-12, 2022. The inaugural members of Entera's CSAB include: Professor John P. Bilezikian; Professor Maria Luisa Brandi; Professor Bart Clarke; Professor Felicia Cosman; Professor William Fraser; Dr. Roger Garceau; Professor Sophia Ish-Shalom; Professor Socrates Papapoulos.

07:48 EDT Founder SPAC reminds shareholders to vote for business combination - Founder SPAC reminds its shareholders to vote in favor of the previously announced business combination with Rubicon Technologies. Shareholders who owned ordinary shares of Founder as of the close of business on May 24, 2022 may vote their shares. Shareholders as of the Record Date continue to have the right to vote their shares, regardless of whether such shareholders subsequently sold their shares and do not own such shares as of the date on which they cast their vote. Founder's board of directors recommends vote "FOR" the Business Combination and each of the other proposals described in the definitive proxy statement/consent solicitation statement/prospectus filed by Founder with the Securities and Exchange Commission on July 6, 2022.

07:46 EDT Equifax to acquire Midigator, terms not disclosed - Equifax is expanding its global footprint in digital identity and fraud prevention with a definitive agreement to acquire Midigator, a provider of post-transaction fraud mitigation solutions. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2022. The acquisition is not anticipated to have a material impact on 2022 Equifax financial results. As part of the transaction, LLR Partners, who invested in Midigator in 2018, will exit the business. Once the transaction closes, Midigator will become part of the Equifax USIS business unit.

07:44 EDT ZW Data Action Technologies partners with Forbes Global Alliance - ZW Data Action Technologies announced that it entered into a cooperation agreement with Forbes Global Alliance, FGA, to build the Forbes China Group Digital Collection Platform to launch NFT Products and jointly operate the platform data by leveraging the two parties' respective capital, platform and resource advantages. This cooperation with FGA is another important initiative for the Company to continue its expansion to the NFT marke. The Company will establish a digital collection platform for FGA, and co-release a limited number of FGA's NFT products, offering services including but not limited to web hosting, digital marketing and content delivery. "The emergence of NFT has changed the traditional virtual commodity trading model, and the cooperation with FGA is a new attempt of ZW Data in NFT + digital publishing. We envisage that we are able to launch more digital assets online through the NFT platform by building a multi-industry blockchain application platform, as we always aim to expand NFT applications to more industries, promote NFT development and enhance the value of traditional industries. The global NFT trading volume has been increasing since 2021... We are confident about the future development of NFT market and believe that this cooperation with FGA will largely benefit our revenue growth going forward," commented Handong Cheng, Chairman and Chief Executive Officer of ZW Data.

07:43 EDT BridgeBio announces interim results from Phase 2 trial of infigratinib - BridgeBio Pharma announced interim results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia. Achondroplasia is the most common cause of disproportionate short stature. Achondroplasia impacts health and can lead to medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis, and spinal stenosis. Achondroplasia affects approximately 55,000 people in the United States and Europe, including up to 13,000 children and adolescents with open growth plates. The condition is uniformly caused by an activating mutation in fibroblast growth factor receptor 3. Infigratinib is an oral small molecule that inhibits FGFR3, therefore designed to target this well-described disease at its source. At the highest dose level evaluated to date, mean increase in annualized height velocity was 1.52 cm/yr over baseline for all follow-up data available at time of data cut in children 5 years of age and older. In this group, 64% were responders and the average percent change from baseline in AHV was 60%. Earlier cohorts in PROPEL 2 did not achieve the target efficacious exposure as suggested by our preclinical data and no dose response was observed. An increase in AHV over baseline of 0.22 cm/yr was observed across these earlier combined cohorts for children 5 years of age and older. PROPEL 2 enrolled children as young as 3 years of age in the study. Consistent with other trials in the younger age population, both AHV and height Z-scores were analyzed to help control for greater variability in growth seen by age and sex in children 3 to less than5 years old. In this age group, the average increase in ACH height Z-score at 6 months was 0.21 standard deviation score and an increase in AHV of 0.61 cm/yr over baseline was observed. Across Cohort 4, the median duration of follow-up was 26.9 weeks at time of data cut. Median follow-up across the entire study is 48.1 weeks across 62 participants included in the safety population at time of data cut. No treatment-related SAEs have been reported to date in any cohort. 90.3% of participants experienced at least one treatment-emergent adverse event, the majority of which were Grade 1, unrelated to study drug, and consistent with a pediatric achondroplasia population. Only 9.7% of participants had a TEAE related to study drug, all of which were Grade 1, and included dyspepsia, decreased appetite, flatulence, hypercholesterolemia, hyperphosphatemia, and vitamin D decrease. A single case of mild hyperphosphatemia led to a dose reduction in a participant in Cohort 3, the only dose adjustment made to date in the study. Phosphorus levels for this participant only exceeded upper limit of normal by less than10% and returned to and remain normal at the reduced dose. No other cases of hyperphosphatemia have been observed in any other cohort to date, and no trends in phosphorous by dose have been observed. No other AEs required dose modifications or interruptions. No children have discontinued treatment as the result of an adverse event. No bone-related AEs were observed to date. BridgeBio, after discussions with regulatory agencies, has begun enrolling Cohort 5. Cohort 5 participants are receiving approximately twice the dose of Cohort 4. At the conclusion of the ongoing trial, BridgeBio intends to present full data at a medical conference in the first half of 2023. Additionally, BridgeBio expects to evaluate development of infigratinib in other FGFR-driven skeletal dysplasias, which affect more than 50,000 people in the US and Europe, building on this positive interim data from PROPEL 2 as well as preclinical data in hypochondroplasia presented at the Endocrine Society 2022 Annual Conference earlier this year.

07:42 EDT Rekor Systems awarded contract with Florida Department of Transportation - Rekor Systems announced that it has been awarded a contract with the Florida Department of Transportation FDOT Office of Transportation Data and Analytics ,TDA. This contract covers hardware, software and data collection services for the State's Non-Motorized Count Station Installation and Maintenance Services over a five-year term. The contract was executed by Rekor subsidiary Southern Traffic Services, STS, which it acquired in June. Recently, the State of Florida was named as having the most bicycle fatalities among states by the U.S. Department of Transportation and recently was cited as the second most dangerous state for pedestrians by Smart Growth America. To combat this urgent safety risk, the State has put in place an aggressive program to collect and analyze data on non-motorized pedestrian and bicycle traffic across the State. This new contract expands these efforts by using Rekor's advanced monitoring capabilities and AI-enabled analysis to identify trends and changes in real-time traffic that can lead to better solutions. The data collected, which includes volume data and supporting statistics, can be used for analyses in a variety of projects, such as safety studies and planning for FDOT facilities, pavement and trail maintenance.

07:40 EDT Brooklyn ImmunoTherapeutics announces IRX-2 Phase 2 study results - Brooklyn ImmunoTherapeutics announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnosed stage II, III, or IVA squamous cell carcinoma of the oral cavity. The primary endpoint of the study was to estimate 2-year Event-Free Survival with key secondary endpoints of Overall Survival and safety of IRX-2. One hundred and fifty patients were enrolled in the study. At two years of follow-up in the intention-to-treat population the median EFS was 48.3 months and was not reached in the control arm. In key pre-specified subgroups defined by stage and type of adjuvant treatment, outcomes favored IRX-2. Patients in these subgroups were less likely to experience an EFS event in the IRX-2 arm compared to control. Trends in EFS rates as defined by the Kaplan-Meier estimate at two years of follow-up in patients with later stage disease were 57.2 vs 49.4 in favor of IRX-2. In patients that did not receive chemotherapy as part of adjuvant treatment, the EFS Kaplan-Meier estimate at two years of follow-up was 76.4 vs 60.6 in favor of IRX-2. There were no new safety signals observed with IRX-2. Adverse events related to study treatment were higher in the IRX-2 arm than the control arm and were driven primarily by injection site reactions and fatigue. The Company plans to present the results of the INSPIRE study at a scientific conference later this year.

07:38 EDT MyMD Pharmaceuticals announces further advancement of MYMD-1 trial - MyMD Pharmaceuticals announced further advancement of its fully funded Phase 2 clinical trial of lead drug candidate MYMD-1 as a therapy for delaying aging and expanding healthy lifespan. To date, the trial has completed dosing for the first patient cohort and dosing has been initiated in the next higher dose cohort. The trial's Safety Review Committee has confirmed no safety issues and no toxicity in the prior cohort and has voted unanimously to escalate to the next higher dose and begin enrolling the next cohort. The Phase 2 multi-center double-blind, placebo controlled, randomized study investigates the efficacy, tolerability and pharmacokinetics of MYMD-1 in the treatment of chronic inflammation associated with sarcopenia/frailty in participants aged 65 years or older.

07:37 EDT Albertsons provides update on review of potential strategic alternatives - The company said, "In connection with our previously-announced Board led review of potential strategic alternatives to enhance the Company's growth and maximize stockholder value (the "Strategic Alternatives Review"), the Company engaged a third party to review the value of its real estate portfolio. Based on the completed real estate appraisal, the total value of Company-owned and ground-leased properties has increased approximately $2.5 billion to $13.7 billion, up from $11.2 billion in 2019. In addition, as previously disclosed in an 8-K filed June 22, 2022, we entered into an extended lock-up agreement (the "Extended Lock-Up Agreement") with entities affiliated with five of our largest stockholders (Cerberus Capital Management, L.P., Kimco Realty Corporation, Klaff Realty, L.P., Lubert-Adler Partners and Jubilee Limited Partnership), who we refer to as our Sponsors. The Sponsors were each party to the lock-up agreement dated June 25, 2020 (the "2020 Lock-Up Agreement") which was due to expire on June 30, 2022. Under the terms of the Extended Lock-up Agreement, which supersedes the 2020 Lock-Up Agreement, each Sponsor agreed to restrictions, subject to certain exceptions set forth in the Extended Lock-Up Agreement, on its ability to offer, sell, transfer, contract to sell, pledge or otherwise dispose of shares of our common stock that it owns through September 10, 2022, the end of the Company's second fiscal quarter. The Sponsors beneficially own, in the aggregate, 366,043,040 shares of common stock as of the date of this report. The Board has not set a timetable for the conclusion of the Strategic Alternatives Review, nor has it made any decisions related to any further actions or potential strategic alternatives at this time. There can be no assurance that the Strategic Alternatives Review will result in any transaction or other strategic change or outcome."

07:35 EDT Ionis announces FDA accepted NDA for tofersen - Ionis Pharmaceuticals announced that the FDA has accepted a New Drug Application, or NDA, for tofersen, an investigational antisense medicine for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis, or SOD1-ALS. The NDA was submitted by Biogen, which licensed tofersen from Ionis in 2018. The application has been granted priority review and given a Prescription Drug User Fee Act action date of Jan. 25, 2023. The FDA has noted that it is currently planning to hold an Advisory Committee meeting for this application. The average life expectancy for people with ALS is three to five years from time of symptom onset; patients with some SOD1 mutations have an even shorter life expectancy. There is currently no treatment targeted for SOD1-ALS. The tofersen NDA included results from a Phase 1 study in healthy volunteers, a Phase 1/2 study evaluating ascending dose levels, the Phase 3 VALOR study, and the open label extension study.

07:32 EDT FDA accepts Biogen's NDA, grants priority review of tofersen - Biogen announced that the U.S. Food and Drug Administration has accepted a New Drug Application for tofersen, an investigational drug for superoxide dismutase 1 amyotrophic lateral sclerosis. The application has been granted priority review and given a Prescription Drug User Fee Act action date of January 25, 2023. The FDA has noted that it is currently planning to hold an Advisory Committee meeting for this application, on a yet-to-be determined date. The average life expectancy for people with ALS is three to five years from time of symptom onset. There is currently no treatment targeted for SOD1-ALS. Biogen is seeking approval of tofersen under the FDA's accelerated approval pathway, based on the use of neurofilament as a surrogate biomarker that is reasonably likely to predict clinical benefit. Neurofilaments are normal proteins found in healthy neurons, that are increased in blood and cerebrospinal fluid when damage has been done to neurons or their axons and are a marker of neurodegeneration. In ALS, higher levels of neurofilaments have been found to predict more rapid decline in clinical function and shortened survival. Tofersen study results suggest reductions in neurofilament preceded and predicted slowing of decline in measures of clinical and respiratory function, strength, and quality of life. Biogen is committed to ongoing data generation and finalizing the confirmatory data package with the FDA. The tofersen NDA included results from a Phase 1 study in healthy volunteers, a Phase 1/2 study evaluating ascending dose levels, the Phase 3 VALOR study, and the open label extension (OLE) study. Also included are the most current 12-month integrated results from VALOR and the OLE study, recently presented at the European Network to Cure ALS annual meeting. As previously reported in October 2021, VALOR, a six-month Phase 3 randomized study, did not meet the primary endpoint of change from baseline to week 28 in the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale. However, trends of reduced disease progression across multiple secondary and exploratory endpoints were observed. The 12-month integrated data showed that earlier initiation of tofersen led to sustained reductions in neurofilament, a marker of neurodegeneration and slowed decline across multiple efficacy endpoints. In the 12-month data, the most common adverse events in participants receiving tofersen in VALOR and the OLE study were headache, procedural pain, fall, back pain and pain in extremities. Most AEs in both VALOR and the OLE were mild to moderate in severity. Serious neurologic events including myelitis, radiculitis, aseptic meningitis, and papilledema, were reported in 6.7 percent of participants receiving tofersen in VALOR and its OLE. During the FDA review period Biogen will maintain its early access program for tofersen, now with participants in over a dozen countries. The open-label extension and Phase 3 ATLAS study in presymptomatic individuals with a SOD1 genetic mutation remain ongoing. Biogen is actively engaging with other regulators around the world and will provide updates when appropriate.

07:26 EDT Meta Materials appoints Manos Spanos as CBO - Meta Materials announced that Manos Spanos has joined the Company as its first Chief Business Officer. He will oversee business development for META, building scale partnerships and accelerating revenue growth, to establish a global leadership position in the rapidly emerging metamaterials industry. Spanos joins META from L-Nutra.

07:20 EDT Forma Therapeutics announces resignation of CMO Patrick Kelly - In a regulatory filing, Forma Therapeutics said: "On July 20, 2022, Patrick F. Kelly, M.D., Senior Vice President and Chief Medical Officer, and a named executive officer, of Forma Therapeutics Holdings, Inc. provided notice of his resignation from employment with the Company, effective August 3, 2022. Also on July 20, 2022, Selwyn Vickers, M.D., notified the Company of his intent to resign from the Company's Board of Directors, effective July 31, 2022. Dr. Vickers' decision to resign from the Board was not the result of any dispute or disagreement with the Company or the Company's Board on any matter relating to the Company's operations, policies or practices."

07:17 EDT Apollo reports assay results from Calico Silver Project's Waterloo Project - Apollo Silver reports new assay results from the 2022 Drill Program at the Calico Silver Project's Waterloo Property located in San Bernardino County, California. Silver assay results continue to be consistent with the silver grades in the resource block model, illustrating the predictable nature of the silver mineralization. Additionally, gold assay results continue to expand the gold mineralized horizon. "The significance of these results cannot be overstated" Apollo CEO Tom Peregoodoff commented. "We have now received assays from a total of 21 holes and these results have clearly demonstrated the very high correlation between the 2022 drilling to date and the resource block model. This gives me great confidence that the upcoming resource calculation will convert a significant percentage of silver ounces currently classified as inferred to a higher resource classification which will provide a very sound foundation for our future engineering and economic studies."

07:15 EDT Microbix Biosystems presenting STI Multiplex Test Controls at AACC - Microbix Biosystems announces it is presenting about the utility of its multi-pathogen and swab-formatted Quality Assessment Products to monitor molecular assays that detect and distinguish between four sexually-transmitted infections that cause Genital Ulcer Disease, GUD - at the 2022 conference of the American Association of Clinical Chemistry, AACC, taking place in Chicago, Illinois from July 24-28, 2022. Its poster presentation is titled "Novel Herpes Simplex Virus, Varicella Zoster Virus, and Treponema pallidum Quality Control Material for use with Genital Lesion Molecular Detection Assays." The poster details the use of Microbix's PROCEEDx FLOQ HSV1&2/VZV/Syphilis Swab Positive Sample QAPs to monitor the performance, procedures, and workflows of molecular assays that detect STIs from the oral and genital types of the Herpes Simplex Virus, Varicella Zoster Virus and Treponema pallidum. The PROCEEDxFLOQ QAPs proved compatible with 13 molecular assays across both commercially-available diagnostic platforms and laboratory-developed tests, and were used to support an external quality assessment pilot study.

07:13 EDT Freight Technologies awarded Samsung Mexico SDS contract - Freight Technologies was awarded Samsung Mexico SDS business and has begun using its platform to assist with effecting Samsung's shipments from Mexico to the United States. Javier Selgas, CEO of Fr8Tech, said, "Samsung, one of the world's largest producers of electronic devices, selected Fr8App to ship from Mexico cross border to the United States, which we believe validates the Fr8App platform. We believe this is just the beginning of many great things to come."

07:12 EDT Versus Systems announces USPTO granted new patent claims - Versus Systems announces that, pursuant to a Versus filing made in 2019, the U.S. Patent and Trademark Office, USPTO, has now allowed 20 new claims associated with a new patent titled "MANAGING IN-CONTENT CHALLENGES FOR MULTI-PLAYER GAMES." The USPTO has now issued U.S. Patent No. 11,376,498 to Versus to cover games and challenges that produce real world rewards inside of apps and streaming media. Versus' new patented claims protect several methods for managing first and second-screen games inside of apps, television broadcasts, and streaming media, with a focus on how to provide different digital and physical prizes to different players based on their performance in the games and eligibility criteria such as age and location. Versus will be using its patented technologies in-venue, at NFL, NHL, NBA, NCAA, and other sporting events and, beginning in Q4 of this year, in Over-The-Top television and streaming media. "Versus is very proud of its growing patent portfolio around in-game rewards. We are creating innovative, unique technologies for both content creators and audiences," said Matthew Pierce, Founder and CEO of Versus Systems. "The streaming media landscape is changing so fast - from Disney to Amazon to Discovery to the evolving college football landscape, fans should expect a better experience than traditional TV commercials. Content, even branded, sponsored, and ad-supported content, should be more personal, more contextual, and more rewarding. Audiences should be able to earn rewards and prizes that they care about while watching their favorite content. These patents help with that. Our whole portfolio does. We want to make things more fun, and we're eager to use this patented technology to do that."

07:10 EDT Clearside Biomedical completes dosing in OASIS Phase 1/2a trial of CLS-AX - Clearside Biomedical announced completion of dosing in Cohorts 3 and 4 of OASIS, its Phase 1/2a clinical trial of CLS-AX in patients with neovascular age-related macular degeneration. OASIS is a U.S.-based, multi-center, open-label, dose-escalation trial in wet AMD patients to assess the safety and tolerability of a single dose of CLS-AX administered by suprachoroidal injection. The study enrolled 8 patients in Cohort 3 and 8 patients in Cohort 4, all of whom received aflibercept at their first visit and a single dose of CLS-AX at their second visit one month later. In total, there were 27 patients in four cohorts enrolled in OASIS, with escalating doses of CLS-AX. The primary endpoint for the trial will assess the safety and tolerability of CLS-AX for three months following the administration of CLS-AX. There is also an ongoing extension study to follow patients in Cohorts 2, 3 and 4 for three months after their completion of OASIS. "We look forward to providing more data on the potential benefits of combining targeted and compartmentalized suprachoroidal delivery via our SCS Microinjector with the broad pan-VEGF attributes of axitinib," said Thomas Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer. "The completion of enrollment in OASIS is a critical milestone as we look forward to our data readout from the full OASIS trial in the fourth quarter of this year. We are grateful to all our investigators and patients whose time and commitment made this first-in-human, suprachoroidal tyrosine kinase inhibitor trial possible."

07:09 EDT Iridium sees total FY22 service revenue up 7%-9% from $492M last year - Raises FY22 OEBITDA view to $410M-$420M from $400M-$410M. OEBITDA for 2021 was $378.2M. Expects negligible cash taxes in 2022. Cash taxes are expected to be negligible through approximately 2024. Expects net leverage of between 2.5 and 3.5 times OEBITDA at the end of 2023, assuming the completion of the Company's total $600M in authorized share repurchases. Net leverage was 3.4 times OEBITDA at December 31, 2021. Matt Desch, CEO, said, "Based upon the momentum that we continue to see from our extensive global ecosystem of business partners, we are raising our full-year outlook for service revenue growth to between 7% and 9%, and for OEBITDA to between $410M-$420M in 2022."

07:08 EDT Unicycive Therapeutics reports findings of RD survey - Unicycive Therapeutics announced the results from an independent survey of renal dietitians conducted by Spherix Global Insights, an independent business intelligence firm that leverages its own independent data and expertise to provide strategic guidance. The survey canvassed 100 U.S. renal dietitians regarding a variety of topics related to the treatment of their chronic kidney disease and dialysis patients. Findings: Renal Dietitians, RDs, report the highest degree of influence on phosphate binder choice compared to other drug categories; 9.2/10 vs. 7.8/10 for calcimimetics, and 1.9/10 for erythropoiesis-stimulating agents. RDs indicate a high level of interest in the Renazorb product profile;66% indicate "high" interest;96% indicate "high" or "moderate" interest; Most appealing aspects of Renazorb are Efficacy/Potency and Lower Number of pills; 65% agree that patients prefer phosphate binders they can swallow as opposed to having to chew. 65% of RDs rate hyperphosphatemia as the therapeutic area with the greatest unmet need for new products in dialysis patients. "As renal dietitians indicate they have high influence on brand selection for phosphate binders, the results of this survey are an important barometer that further support the potential for Renazorb to be the phosphate binder of choice," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "Renazorb, with its high and rapid phosphate binding and reduced pill burden for better medication compliance, should offer patients an enhanced treatment option while presenting significant commercial potential. Moving forward, we are focused on establishing our global commercial strategy for Renazorb as hyperphosphatemia is a growing medical need worldwide."

07:07 EDT Cyclerion Therapeutics appoints Steven Hyman to board of directors - Cyclerion Therapeutics announced the appointment of Steven E. Hyman, M.D., to its Board of Directors effective July 25. Dr. Hyman will work with Cyclerion leadership to help shape the future of its research and clinical development strategy while expanding external collaborations with scientific leaders and industry partners. Dr. Hyman is a Distinguished Service Professor and the Harald McPike Professor of Stem Cell and Regenerative Biology at Harvard University and a Core Institute Member of the Broad Institute of MIT and Harvard, where he directs the Stanley Center for Psychiatric Research.

07:06 EDT Lionheart III, Security Matters enter business combination agreement - Security Matters, a publicly traded company on the Australian Securities Exchange, and Lionheart III, a publicly traded special purpose acquisition company, today announced that they have entered into a business combination agreement and accompanying scheme implementation deed pursuant to which SMX will list on NASDAQ via a newly-formed Irish company to be named "SMX Public Limited Company." Upon the closing of the Transaction, the ordinary shares and warrants of SMX Ireland are expected to trade on NASDAQ under the new ticker symbols "SMX" and "SMXW", respectively, and SMX shall cease to be quoted on the ASX. Key Figures: Total proforma equity value of the combined group is expected to be $360M. This reflects an implied pre-money valuation of SMX of $200M. SMX shareholders will receive consideration via a scheme of arrangement consisting of an aggregate of 20,000,000 ordinary shares of SMX Ireland being 10.2432 SMX Shares per one share in SMX Ireland, with an issued value of $10.00 per SMX Ireland Share The parties expect a post-Transaction cash balance of $116M after fees and expenses. At the closing, SMX shareholders will own approximately 55.5% of the combined company, if there are no redemptions by Lionheart's public stockholders. The Transaction values SMX at $200M. The Transaction is anticipated to generate proceeds of up to approximately $116M cash, assuming no redemptions by Lionheart's public stockholders. These funds will be used to fund operations and strategic growth opportunities. Scura Partners LLC rendered an opinion to the board of directors of Lionheart that the Consideration is fair from a financial point of view to Lionheart. Under the BCA, a subsidiary of SMX Ireland will merge with and into Lionheart, with Lionheart surviving the merger as a wholly owned subsidiary of SMX Ireland, and existing Lionheart stockholders receiving SMX Ireland Shares and warrants in exchange for their existing Lionheart shares and warrants. Under the SID, SMX has agreed to propose a scheme of arrangement under Part 5.1 of the Corporations Act and capital reduction which, if implemented, will result in all shares in SMX being cancelled in return for SMX Ireland Shares, with SMX then issuing a share to SMX Ireland, subject to the satisfaction of various conditions, including: Receipt of required regulatory approvals; the approval of shareholders of both SMX and Lionheart; no material adverse effect, prescribed events or breaches of representations and warranties; and interdependence of the SID and BCA completing successfully; and other customary conditions to a scheme of arrangement, such as Australian court approval and an independent expert confirming that the transaction is in the best interests of SMX shareholders. All options on issue in the SMX Employee Share Option Plan will be cancelled by private agreement and the holders of the ESOP options will be issued equivalent options in SMX Ireland. In addition, SMX has agreed to have non-ESOP options in SMX cancelled by private agreement or if necessary implement an option scheme under Part 5.1 of the Corporations Act which, if implemented, will result in the SMX options held by participants in the Option Scheme being cancelled, and such participants receiving SMX Ireland Shares on the basis of a Black-Scholes valuation for each tranche, subject to SMX option holder approval, court approval and the satisfaction of various conditions. The SID contains customary exclusivity provisions in favour of both parties including 'no-shop' and 'no-talk' restrictions, 'no due diligence', a notification obligation, and matching right. The board of directors of Lionheart has unanimously approved the Transaction. The board of directors of SMX considers the Transaction to be in the best interest of SMX shareholders and option holders and unanimously recommends that SMX shareholders vote in favour of the Scheme and Capital Reduction and SMX option holders vote in favour of the Option Scheme, in the absence of a superior proposal and subject to an independent expert concluding in the independent expert's report that the Scheme is in the best interests of SMX shareholders and option holders. Haggai Alon will be appointed as CEO of SMX Ireland, the parent of the SMX Group and its subsidiaries.

07:06 EDT Nuwellis announces submission of AVOID-HF analysis as trial at HFSA - Nuwellis announced the submission of the AVOID-HF clinical study analysis using the Finkelstein-Schoenfeld method of Win-Ratios as a Late Breaking Clinical Trial at the Heart Failure Society of America's, HFSA, 2022 Annual Scientific Meeting in September. The AVOID-HF prospective, multicenter, randomized controlled trial tested the hypothesis that patients hospitalized for heart failure and treated with ultrafiltration would have a longer time to their first heart failure event within 90 days after hospital discharge compared to those receiving IV loop diuretics. The study was trending favorably when the study sponsor terminated it before reaching full enrollment for reasons unrelated to patient safety or clinical futility. At the time, analysis of the AVOID-HF trial data was inconclusive due to the lower-than-planned sample size. However, newer statistical methods like the Finkelstein-Schoenfeld method of hierarchical Win Ratios increase statistical precision to evaluate the clinical benefit and demonstrate significance between treatment arms with the added benefit of requiring a smaller study sample size. "The Win-Ratios analysis of the AVOID-HF clinical study will provide additional evidence to support the use of ultrafiltration to treat fluid-overloaded heart failure patients," said Nestor Jaramillo, Jr., President and CEO of Nuwellis. "We're grateful to Drs. Pinney, DeVita, and Costanzo, the authors of this manuscript, for leading this reanalysis of the AVOID-HF data. As a company, we are committed to the ultimate goal of making Aquadex therapy the standard of care for fluid management in heart failure patients that are resistant to diuretics. We hope the AVOID-HF Win-Ratios analysis is accepted as a Late Breaking Clinical Trial at HFSA, and we are excited to share these results with the broader heart failure community."

07:04 EDT Electra Battery Materials signs Benefits Agreement with the Metis Nation - Electra Battery Materials announced that it has signed a Benefits Agreement with the Metis Nation of Ontario, or MNO, solidifying a relationship between the two parties and providing employment, training, procurement, and business opportunities related to the construction and expansion of the Company's battery materials refinery north of Toronto Temiskaming Shores. In connection with the Benefits Agreement, Electra has agreed to issue 20,000 common shares of the Company to the MNO as a means of providing a measure of economic participation in the success of Electra's low-carbon battery materials visions. The issuance of the common shares remains subject to the approval of the TSX Venture Exchange. Once issued, the common shares will be subject to a statutory hold period of four-months-and-one-day in accordance with applicable securities laws. Electra is advancing with the commissioning of a battery materials refinery in Temiskaming Shores, Ontario with a plant capacity of 5,100 tonnes of cobalt in sulfate. In concert with its effort to commission the refinery, Electra intends to launch a battery materials recycling demonstration plant in the fall of 2022.

07:02 EDT McDonald's planning for a 'wide range' of scenarios - "The McDonald's System continues to demonstrate strength and resiliency," said McDonald's President and CEO, Chris Kempczinski. "Our second quarter performance reflects outstanding execution against our Accelerating the Arches strategy. By focusing on our customers and crew, enabled by a rapidly growing digital capability, we delivered global comparable sales growth of nearly 10%. Nonetheless, the operating environment across the competitive landscape remains challenging. While we are planning for a wide range of scenarios, I am confident that our plans and people position McDonald's to weather this environment better than others."

07:02 EDT Bausch + Lomb enrolls first patient in Technolas Teneo excimer laser study - Bausch + Lomb announced that the company has enrolled the first patient in a study evaluating the safety and efficacy of the Technolas Teneo excimer laser for laser-assisted in situ keratomileusis, or LASIK, vision correction surgery for hyperopia with astigmatism.

07:02 EDT McDonald's reports Q2 global comp sales up 9.7% - Global comparable sales increased 9.7%, reflecting positive comparable sales across all segments: U.S. increased 3.7%; International Operated Markets segment increased 13.0%; International Developmental Licensed Markets segment increased 16.0%. Systemwide sales increased 4%.

06:51 EDT International Game launches iLottery games in Michigan - International Game announced that its subsidiary, IGT Global Solutions Corporation, has signed an agreement to deliver iLottery content through its remote gaming server to the Michigan Lottery.

06:50 EDT Spire Global awarded $1.7M NOAA contract - Spire Global announced that it has been awarded a Commercial Weather Data Pilot space weather contract as part of the Commercial Data Program issued by the National Oceanographic and Oceanic Administration. Spire will provide near real-time radio occultation (RO) data for NOAA's space weather forecast models to measure ionospheric conditions that impact activities such as aviation, satellite operations, navigation, and communications. The award, valued at $1.7M, represents Spire's continued ability to provide high quality commercial data for NOAA's weather forecast models. NOAA's CWDP studies using Spire's data are expected to last 12 months.

06:48 EDT MSCI raises FY22 CapEx view to $65M-$75M from $60M-$70M - Cuts FY22 net cash from operating activities view to $1.08B-$1.12B from $1.12B-$1.16B. Cuts FY22 free cash flow view to $1.005B-$1.055B from $1.05B-$1.1B.

06:46 EDT MSCI raises quarterly dividend 20.2% to $1.25 per share - Payable on August 31 to shareholders of record as of the close of trading on August 12.

06:35 EDT MediciNova begins Phase 2 clinical trial to evaluate MN-001 - MediciNova announced the initiation of a Phase 2 clinical trial to evaluate MN-001, or tipelukast, for the treatment of patients with non-alcoholic fatty liver disease, or NAFLD, type 2 diabetes mellitus, or T2DM, and hypertriglyceridemia. Kazuko Matsuda, Chief Medical Officer of MediciNova, commented, "We are very pleased that this Phase 2 trial evaluating MN-001 has commenced. MN-001 appears to reduce serum lipid profiles in patients with a dual diagnosis of NAFLD and T2DM/prediabetes with dyslipidemia. The efficacy and safety data from this trial, if successful, could lead to a pivotal Phase 3 trial intended to support an NDA for MN-001 to treat dyslipidemia and reduce liver fat content in patients with NAFLD with T2DM/prediabetes."

06:27 EDT GE likely to push out $1B of free cash flow into the future - GE said: "GE continues to trend toward the low end of its 2022 outlook on all metrics except free cash flow. Working capital will be pressured as GE protects customers from the impact of supply chain challenges, as well as Renewable Energy-related orders, which together are likely to push out approximately $1 billion of free cash flow into the future."

06:25 EDT General Electric 'on track' to launch three independent companies

06:16 EDT Polaris CEO says 'we continue to see a healthy consumer and stable demand' - Mike Speetzen, CEO of Polaris said, "Our results during the second quarter reflect our team's commitment to our customers through industry-leading innovation and exceptional execution, despite the ongoing supply chain constraints impacting the global economy. While we are closely watching a number of demand indicators to understand the resilience of the consumer in this environment, we continue to see a healthy consumer and stable demand. In the quarter, some easing of logistics complexities, commodity costs, and certain supply chain bottlenecks helped to support sequential margin improvement and increased shipment volume. While this trend is expected to continue in the back half of the year, we remain diligent and prepared to respond if headwinds materialize. Our focused strategy of being the leading player in powersports, coupled with the significant opportunity to get back to optimal dealer inventory levels, gives us confidence in our ability to drive continued performance for Polaris and value creation for our shareholders."

06:11 EDT Buxton Helmsley sends letter to Endo directors relating to financial disclosures - The Buxton Helmsley Group, the New York City-based investment advisor to clients with financial interests in Endo International, issued an open letter to directors of the company and its financial auditor, PricewaterhouseCoopers LLP, relating to financial disclosures. Reference Link

06:09 EDT Tutor Perini announces apparent low bid for Raritan River Bridge project - Tutor Perini announced that it has been identified as the apparent low bidder for New Jersey Transit's Raritan River Bridge Replacement Project, with a submitted bid valued at approximately $519M. The Raritan River Bridge Replacement Project will replace the 114-year-old bridge, connecting South Amboy, NJ and Perth Amboy, NJ, which was damaged by Superstorm Sandy in 2012. The new bridge will integrate resilient structural designs and materials to withstand future storm surges and be significantly less vulnerable to severe weather events. The project scope of work includes construction of the lift bridge and flanking spans superstructure, communications and signal systems, and overhead catenary work, as well as miscellaneous civil and structural work, wetland mitigation work and the demolition of the existing bridge as necessary to construct the bridge fender system as well as to provide a fully functioning navigational channel beneath the newly constructed bridge. Contract award is anticipated in the fourth quarter of 2022, with commencement of work to subsequently follow.

06:02 EDT UPS raises targeted share repurchases to $3B from $2B for 2022

05:21 EDT AbbVie announces EC approval for Rinvoq - AbbVie announced the European Commission, or EC, approved Rinvoq for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

05:16 EDT ViaSat subsidiary selected by ESA to conduct SATCOM study - Viasat UK, a subsidiary of Viasat, announced it was selected by the European Space Agency, or ESA, to conduct a multi-layered Satellite Communication, or SATCOM, study focused on evaluating the use cases, market segments and technical aspects of these future systems, which will be comprised of networks that span multiple orbital types including Geostationary Equatorial Orbit, or GEO, Medium Earth Orbit, or MEO, Low Earth Orbit, or LEO, High Altitude Platform Systems, or HAPS, and others, as well as include various frequency bands, satellite operators and network designs. This research program is expected to be completed in the second quarter of 2023.

05:12 EDT SMX Ireland to trade on Nasdaq though Lionheart III combination - Australian technology company Security Matters announced its business combination with Lionheart III Corp. (LION), a special acquisition purpose company. The combined Nasdaq entity is expected to be valued at $360M. The combined entity will list on Nasdaq via a newly-formed Irish company to be named SMX Ireland. Upon the closing of the business combination, the ordinary shares and warrants of SMX Ireland are expected to trade on Nasdaq under the new ticker symbols (SMX) and (SMXW), respectively, and SMX shall cease to be quoted on the Australian Stock Exchange, or ASX. The value reflects an implied pre-money valuation of the company on the ASX of $200M and is anticipated to generate proceeds of up to approximately $116M, assuming no redemptions by Lionheart's public stockholders. The combined entity is expected to commence trading on Nasdaq in Q4.